phylogenet
analys
provid
strong
evid
amino
acid
chang
spike
protein
anim
human
sar
coronavirus
sarscov
two
zoonot
transfer
result
posit
select
sever
studi
support
amino
acid
chang
anim
human
virus
result
interspeci
adapt
role
neutral
antibodi
nab
drive
sarscov
evolut
particularli
intraspeci
transmiss
unknown
detail
examin
sarscov
infect
anim
human
convalesc
sera
could
provid
evid
nab
pressur
found
may
lead
strategi
effect
block
viru
evolut
pathway
broaden
activ
nab
show
focus
domin
neutral
epitop
contemporaneousand
crossstrain
nab
respons
sarscov
spike
protein
exist
natur
infect
vitro
immun
pressur
epitop
use
strainspecif
nab
recapitul
domin
escap
mutat
present
anim
human
virus
strategi
block
nab
escapenatur
occur
evolut
pathway
gener
broad
nab
bnab
activ
escap
mutant
strain
explor
structurebas
amino
acid
chang
activationinduc
cytidin
deaminas
aid
hot
spot
light
chain
cdr
complementar
determin
region
alon
introduc
shuffl
natur
occur
nonimmun
human
vl
chain
repertoir
target
mutagenesi
success
gener
bnab
result
demonstr
nabmedi
immun
pressur
like
drive
forc
posit
select
intraspeci
transmiss
sarscov
somat
hypermut
shm
singl
vl
cdr
markedli
broaden
activ
strainspecif
nab
strategi
investig
studi
particular
use
structur
inform
combin
chainshuffl
well
hotspot
cdr
mutagenesi
exploit
broaden
neutral
activ
improv
antivir
nab
therapi
directli
manipul
viru
evolut
citat
sui
j
aird
dr
tamin
murakami
yan
et
al
broaden
neutral
activ
directli
block
domin
antibodydriven
sarscoronaviru
evolut
pathway
plo
pathog
openaccess
articl
distribut
term
creativ
common
public
domain
declar
stipul
place
public
domain
work
may
freeli
reproduc
distribut
transmit
modifi
built
upon
otherwis
use
anyon
law
purpos
novel
coronaviru
cov
sever
acut
respiratori
syndrom
coronaviru
sarscov
caus
worldwid
epidem
sar
fatal
rate
later
reemerg
result
infect
four
individu
full
recoveri
winter
sarscov
demonstr
zoonot
diseas
evolv
palm
civet
human
host
global
outbreak
occur
cluster
sar
case
result
two
independ
zoonot
transfer
palm
civet
human
although
palm
civet
identifi
host
involv
human
transmiss
evid
suggest
exist
anoth
precursor
reservoir
inde
bat
predominantli
horsesho
bat
later
found
natur
reservoir
sarslikecov
harbor
divers
virus
host
variant
sarslikecov
circul
bat
may
cross
speci
barrier
threat
enhanc
larg
number
bat
often
congreg
broad
geograph
distribut
abil
travel
long
distanc
divers
host
rang
variant
immun
pressur
within
natur
reservoir
intermedi
host
like
continu
drive
sarscov
evolut
phylogenet
analys
provid
clear
evid
amino
acid
chang
spike
protein
anim
human
virus
obtain
two
zoonot
transfer
result
posit
select
studi
suggest
gene
underw
strong
posit
select
adapt
human
host
interspeci
transmiss
posit
select
pressur
transmiss
within
speci
also
clearli
demonstr
role
nabmedi
immun
pressur
play
drive
posit
select
particularli
intraspeci
transmiss
still
unknown
last
sever
year
neutral
human
monoclon
antibodi
mab
develop
potenti
therapeut
prophylaxi
treatment
sar
nabsmedi
protect
also
prevent
escap
mutant
virus
cytotox
tlymphocyt
commonli
associ
rapid
diseas
progress
sever
although
recent
sarscov
outbreak
desir
develop
effect
abbas
passiv
immunotherapi
zoonot
respiratori
pathogen
might
continu
evolv
immun
pressur
within
anim
kingdom
potenti
rapidli
adapt
human
previous
develop
potent
human
nab
protein
civet
human
viral
strain
demonstr
profound
protect
viral
infect
sarscov
mous
model
studi
reveal
recogn
conform
sensit
epitop
locat
within
receptor
bind
domain
rbd
comprehens
neutral
sensitivityresist
profil
also
establish
base
detail
epitop
map
cocrystallograph
structur
studi
paper
use
nab
detail
knowledg
epitop
examin
nab
respons
convalesc
serum
sampl
chronic
expos
civet
farmer
sar
outbreak
patient
civet
cat
studi
provid
first
evid
contemporan
strainspecif
crossstrain
nab
respons
protein
present
natur
civet
cat
human
infect
vitro
neutral
escap
studi
recapitul
highli
conserv
escap
mutat
also
occur
natur
virus
regardless
host
speci
structur
featur
human
nab
requir
broaden
activ
includ
bind
escap
mutant
also
investig
inde
among
sever
differ
approach
examin
amino
acid
chang
singl
activationinduc
cytidin
deaminas
aid
hot
spot
light
chain
cdr
alon
introduc
shuffl
natur
occur
nonimmun
human
variabl
light
chain
vl
target
cdr
mutagenesi
suffici
gener
broad
nab
bnab
rang
viral
strain
includ
neutral
escap
variant
result
import
implic
manag
new
emerg
viral
pathogen
provid
strategi
directli
manipul
viru
evolut
ab
blockad
escap
pathway
eleven
randomli
select
serum
sampl
patient
develop
sar
outbreak
analyz
neutral
activ
protein
pseudotyp
virus
protein
viral
strain
use
repres
late
phase
outbreak
human
case
respect
phylogenet
analysi
differ
viral
isol
human
patient
civet
two
epidem
demonstr
close
relationship
civet
closer
civet
though
serum
sampl
outbreak
abl
neutral
pseudotyp
virus
potenc
quit
differ
fig
patient
serum
sampl
statist
significantli
potent
neutral
contrast
statist
analysi
civet
cat
sera
show
higher
neutral
activ
compar
fig
addit
neutral
activ
found
three
four
outbreak
patient
sera
slightli
higher
strain
compar
fig
interestingli
surveil
sera
sampl
collect
civet
cat
farmer
june
period
outbreak
show
neutral
titer
like
owe
chronic
exposur
sarslikecov
fig
bind
activ
serum
sampl
also
test
unexpectedli
higher
bind
activ
civet
cat
farmer
serum
seen
patient
sera
fig
comparison
abil
differ
serum
sampl
compet
bind
show
patient
sera
compet
bind
significantli
stronger
serum
sampl
fig
taken
togeth
two
latter
observ
suggest
larger
percentag
direct
ab
serum
sampl
nab
serum
sampl
result
also
demonstr
contemporaneousstrain
crossstrain
nab
produc
human
anim
follow
natur
sarscovsarslikecov
infect
molecular
evolut
studi
sarscov
outbreak
two
zoonot
transfer
provid
evid
posit
select
pressur
gene
vitro
neutral
escap
studi
use
strain
specif
nab
perform
simul
humor
immun
pressur
vivo
incub
plaqu
purifi
sarscov
urbani
use
total
isol
plaqu
pick
viabl
virus
obtain
four
plaqu
three
passag
cell
cultur
virus
confirm
concentr
greater
need
neutral
wildtyp
virus
sequenc
complet
gene
four
variant
reveal
one
common
mutat
amino
acid
posit
three
variant
carri
mutat
lysin
alanin
one
mutat
lysin
glycin
although
four
mutat
also
shown
protein
none
appear
four
escap
variant
locat
outsid
rbd
tabl
sarscov
caus
worldwid
epidem
sar
respons
zoonot
infecti
diseas
role
neutral
antibodi
nab
mediat
immun
pressur
evolut
sarscov
outbreak
second
zoonot
transmiss
unknown
demonstr
nab
respons
elicit
natur
infect
clearli
strainspecif
compon
could
drive
forc
viru
evolut
spike
protein
intraspeci
transmiss
vitro
immun
pressur
use
strainspecif
nab
recapitul
domin
escap
mutat
present
anim
human
virus
investig
gener
singl
broad
nab
bnab
activ
variou
natur
viral
variant
outbreak
well
nab
escap
mutant
remark
amino
acid
chang
activationinduc
cytidin
deaminas
aid
hot
spot
somat
hypermut
local
singl
vl
cdr
success
gener
bnab
result
provid
effect
strategi
gener
bnab
gener
use
improv
immun
base
antivir
therapi
well
provid
foundat
directli
manipul
viru
evolut
block
escap
pathway
neutral
activ
serum
sampl
analyz
pseudotyp
virus
bear
protein
indic
dilut
data
shown
box
whisker
graph
box
extend
percentil
percentil
line
median
whisker
box
indic
percentil
dot
box
show
highest
lowest
data
point
symbol
indic
data
point
sarscov
neg
healthi
human
serum
sampl
patient
serum
calcul
statist
analysi
done
valu
use
one
way
anova
correl
sampl
data
present
statist
analysi
previous
describ
chang
complet
abolish
bind
protein
rbd
fragment
key
residu
form
neg
charg
bind
interfac
patch
mutat
affect
bind
rbd
protein
human
receptor
viral
replic
vero
cell
data
shown
therefor
clear
mutat
suffici
confer
resist
without
cost
gain
viral
fit
human
host
importantli
mutat
aros
select
pressur
coincid
chang
protein
virus
virus
tabl
obtain
evid
natur
occur
human
anim
nab
domin
neutral
escap
pathway
appear
occur
natur
sar
sarslik
cov
infect
sought
isol
new
bnab
panact
strain
well
escap
variant
identifi
structur
featur
uniqu
andor
common
broad
activ
signatur
amino
acid
differ
protein
posit
strain
provid
finit
way
interrog
breadth
nab
bind
neutral
activ
tabl
identif
nab
initi
use
bait
isol
crossstrain
nab
could
recogn
promiscu
amino
acid
posit
five
uniqu
antibodi
identifi
pan
two
nonimmun
human
ab
phage
display
librari
neutral
activ
test
pseudotyp
virus
one
found
potent
nab
fig
kinet
analysi
igg
bind
demonstr
high
affin
interact
k
nm
fig
also
potent
inhibit
bind
express
cell
fig
epitop
map
show
two
amino
acid
region
critic
import
bind
singl
amino
acid
chang
either
posit
result
complet
loss
bind
fig
amino
acid
chang
posit
affect
bind
data
shown
basi
result
civet
virus
also
recogn
neutral
sinc
tabl
contrast
affect
chang
posit
shown
fig
locat
ridg
form
extend
loop
reinforc
cy
cy
disulfid
bond
suggest
recogn
slightli
differ
neutral
epitop
sinc
cdr
residu
make
contact
segment
rbd
identif
ab
parallel
effort
rbd
coat
immmunotub
conjug
magnet
bead
use
pan
target
togeth
third
nonimmun
scfv
librari
isol
desir
bnab
pan
bead
result
specif
elisa
posit
clone
one
clone
scfv
bound
cellsurfac
express
fulllength
protein
show
neutral
activ
pseudotyp
virus
data
shown
convert
method
use
follow
panel
b
b
neutral
assay
pseudotyp
virus
six
civet
serum
sampl
collect
anim
market
guangzhou
jan
similarli
fig
indic
data
point
sarscov
neg
civet
cat
serum
sampl
c
neutral
assay
pseudotyp
virus
four
serum
sampl
outbreak
sampl
label
graph
patient
patient
describ
ten
serum
sampl
civet
cat
farmer
collect
june
guangdong
provinc
analyz
pseudotyp
virus
e
rbd
bind
activ
outbreak
civet
cat
farmer
serum
sampl
analyz
elisa
serum
sampl
use
panel
c
respect
dilut
serum
data
present
way
panel
unpair
student
ttest
use
statist
analysi
averag
standard
deviat
sd
background
bind
two
sarscov
neg
human
serum
sampl
ctrlh
also
shown
f
comparison
competit
abil
differ
serum
sampl
bind
evalu
elisa
dilut
sampl
nonspecif
competit
bind
torrbd
two
ctrl
hs
one
control
civet
cat
serum
ctrlc
also
shown
serum
sampl
correspond
use
panel
b
c
data
present
statist
analysi
done
way
panel
e
whole
human
test
separ
neutral
virus
shown
fig
neutral
activ
highest
ab
concentr
test
mgml
also
inhibit
viral
entri
much
less
potent
margin
neutral
furthermor
show
even
lower
neutral
titer
microneutr
assay
tabl
use
urbani
equival
wild
type
escap
virus
may
explain
least
part
conform
differ
recombin
protein
pseudotyp
natur
viru
interestingli
kinet
studi
show
high
bind
affin
three
rbd
fig
discrep
high
bind
affin
ab
weak
pseudomicro
neutral
activ
could
also
due
conform
differ
altern
could
base
mechan
neutral
direct
competit
bind
shown
fig
ab
compet
cellsurfac
receptor
bind
left
panel
dramat
augment
bind
right
panel
expect
epitop
also
distinct
neither
compet
fig
left
bind
fig
structurebas
approach
broaden
neutral
spectrum
light
chain
shuffl
focus
mutagenesi
structur
data
guid
differ
approach
engin
broadli
neutral
activ
outbreak
strain
cocryst
structur
complex
show
lie
center
interfac
addit
contact
residu
locat
vk
light
chain
particular
make
intermolecular
salt
bridg
flank
two
neutral
residu
hbond
contact
residu
notabl
amino
acid
form
part
wrci
hot
spot
motif
aidmedi
somat
hypermut
shm
mutat
germlin
serin
fig
suggest
firstli
natur
mutat
within
hot
spot
would
like
exist
circa
member
nonimmun
vkappa
vk
repertoir
secondli
focus
mutagenesi
hot
spot
would
also
provid
experiment
system
test
whether
mutat
within
region
would
broaden
bind
neutral
activ
accordingli
two
direct
approach
vk
light
chain
shuffl
cs
amino
acid
focus
mutagenesi
fm
simultan
util
identifi
natur
direct
variat
critic
vk
contact
amino
acid
respect
two
phage
display
librari
construct
select
differ
rbd
tabl
clone
bound
four
variant
protein
rbd
character
five
uniqu
ab
identifi
studi
follow
pan
remark
common
featur
uniqu
ab
recov
amino
acid
chang
region
posit
import
contact
residu
rbd
one
consensu
chang
cs
mutant
posit
fig
ab
maintain
germlin
germlin
respect
result
provid
evid
critic
import
contact
residu
spike
protein
bind
specif
addit
find
ab
also
select
use
vl
origin
rearrang
germlin
gene
parent
ab
fig
suggest
type
vl
structur
may
provid
critic
pattern
recognit
motif
epitop
necessari
creat
function
bind
site
deriv
librari
pan
three
rbd
target
five
clone
posit
elisa
four
target
includ
chosen
character
amino
acid
sequenc
clone
shown
fig
four
fm
ab
identifi
one
pan
consist
result
studi
four
fm
ab
srn
chang
posit
five
maintain
mutat
found
parent
thu
hot
spot
inde
central
import
control
breadth
bind
activ
next
eight
scfv
convert
human
mab
test
neutral
pseudotyp
virus
shown
fig
b
among
three
csab
five
fmab
rrn
chang
posit
associ
increas
potenc
wherea
rre
charg
revers
found
potent
fmab
ab
show
less
broad
weak
neutral
activ
thu
use
neg
control
use
posit
control
respect
b
kinet
character
bind
spike
rbd
bind
kinet
evalu
similarli
describ
fig
b
c
competit
bind
cell
left
competit
bind
cell
ugml
controlig
fill
purpl
use
stain
cell
scfv
control
use
ugml
compet
bind
right
competit
bind
cell
assay
fig
except
use
ab
competit
elisa
assay
fix
amount
scfv
express
phage
mix
variou
scfvfc
antibodi
fulllength
indic
antibodi
concentr
mixtur
ad
left
right
coat
elisa
plate
competit
bind
rbd
determin
measur
remain
bind
use
antibodi
homolog
use
posit
control
show
competit
bind
show
inhibit
bind
either
csand
fmlibrari
strategi
result
isol
bnab
activ
four
rbd
variant
kinet
chang
rbd
bind
result
broaden
neutral
activ
five
potent
nab
evalu
bind
kinet
affin
variou
rbd
kinet
data
obtain
bind
abcaptur
biosensor
surfac
evalu
use
bind
model
two
state
conform
chang
model
tabl
fig
csab
kinet
data
fit
bind
model
perfectli
interact
fmab
exhibit
doubl
exponenti
pattern
due
heterogen
ab
therefor
kinet
analys
ab
use
two
state
conform
chang
model
present
suggest
conform
chang
may
occur
format
initi
bind
complex
bind
csfm
mutant
kinet
paramet
deriv
bind
model
due
poorer
respons
nab
kinet
could
accur
deriv
howev
affin
determin
steadi
state
affin
model
biosensorgram
present
qualit
comparison
fig
tabl
summar
kinet
affin
deriv
differ
nab
model
note
affin
ab
onefold
lower
howev
nab
gain
crossreact
also
exhibit
similar
high
affin
potent
nab
bind
mm
affin
bind
neither
bind
comparison
ab
circa
lower
affin
maintain
high
affin
bind
highest
affin
bind
ab
isol
molecular
phylogen
analys
provid
evid
posit
select
pressur
behind
evolut
sarscov
gene
two
epidem
howev
direct
evid
nabmedi
immun
pressur
one
main
drive
forc
viru
evolut
especi
intraspeci
transmiss
lack
studi
focus
critic
neutral
epitop
demonstr
contemporaneousstrain
crossstrain
nab
respons
coexist
natur
sarscov
infect
civet
cat
human
addit
vitro
nab
escap
studi
provid
strong
support
exist
natur
nab
driven
evolut
pathway
moreov
structurebas
shuffl
somat
hypermut
hot
spot
target
mutagenesi
success
gener
bnab
activ
escap
mutant
well
strain
nab
respons
measur
convalesc
serum
chronic
expos
civet
farmer
sar
patient
civet
cat
prototyp
sarscov
strain
repres
two
zoonot
transfer
human
nab
level
convalesc
serum
sar
patient
higher
contemporan
viral
strain
repres
strain
similarli
civet
cat
serum
higher
nab
level
strain
strain
addit
higher
percentag
direct
ab
patient
serum
compet
epitop
compar
chronic
expos
asymptomat
civet
farmer
serum
similar
nab
titer
strain
fig
patient
serum
sampl
also
figur
broadli
neutral
activ
csand
fmab
sequenc
comparison
eight
ab
identifi
fm
librari
select
amino
acid
sequenc
identifi
target
librari
select
five
fmab
target
librari
select
b
neutral
activ
eight
ab
fulllength
test
pseudotyp
virus
use
fig
better
compet
epitop
serum
sampl
test
fig
result
demonstr
crossneutr
activ
present
serum
sampl
suggest
neutral
epitop
conserv
meanwhil
nab
respons
elicit
natur
infect
clearli
strainspecif
compon
inde
viral
strain
specif
nab
found
higher
level
serum
sampl
sampl
anim
human
nab
natur
deriv
memori
bcell
sar
patient
could
neutral
report
among
nab
repres
six
function
group
base
viru
strain
crossreact
five
nab
group
iii
like
abil
neutral
human
isol
outbreak
although
unknown
depend
nab
similar
identifi
probabl
donor
expos
prototyp
isol
amino
acid
particular
interest
group
vi
contain
four
bnab
human
anim
virus
outbreak
strain
studi
demonstr
nab
differ
activ
produc
serum
natur
infect
host
suggest
neutral
activ
repres
sum
polyclon
nab
respons
importantli
memori
b
cell
produc
bnab
eg
group
vi
elicit
natur
sarscov
infect
may
contribut
small
percentag
four
total
nab
circul
nab
potenti
role
human
nab
protect
sarscov
infect
establish
sever
group
consequ
high
mutat
rate
rna
virus
activ
nab
dramat
impact
neutral
escap
variant
sarscov
vitro
immun
pressur
readili
gave
rise
escap
variant
one
amino
acid
posit
acquisit
phenotyp
mutat
neutral
viral
replic
fit
permiss
cell
posit
identifi
posit
select
site
adapt
human
host
howev
mutat
coincid
chang
protein
virus
virus
tabl
nab
pressur
ab
group
iii
ab
exist
natur
could
give
rise
intermedi
escap
mutant
may
continu
evolv
immun
pressur
strain
strain
inde
phylogeni
analysi
gene
civet
civet
indic
posit
select
animaltoanim
transmiss
thu
civet
nabsmedi
immun
pressur
could
major
drive
forc
posit
select
evolut
common
ancestr
strain
broaden
activ
human
nab
either
natur
bcell
hypermut
synthet
ab
engin
includ
bind
escap
mutant
addit
viral
strain
could
one
way
interfer
viral
evolut
pathway
effici
control
viru
infect
human
first
step
isol
bnab
activ
escap
mutant
well
strain
three
larg
nonimmun
abphag
librari
use
pan
variant
rbd
protein
sinc
share
escap
mutant
hypothes
select
may
gener
new
nab
also
resist
mutant
nab
identifi
highaffin
bind
potent
neutral
neutral
viral
infect
includ
mutant
data
tabl
kinet
ab
interact
affin
ab
bind
shown
similar
rational
employ
isol
bnab
use
librari
select
one
ab
extraordinari
bind
affin
poor
neutral
activ
particularli
latter
strain
isol
unlik
nab
compet
rbd
bind
result
demonstr
strategi
de
novo
select
nonimmun
librari
differ
viral
spike
protein
neither
effici
suffici
gener
bnab
desir
extend
spectrum
activ
whether
limit
de
novo
select
bnab
overcom
use
immun
librari
sarscov
infect
patient
remain
determin
structur
data
obtain
scfv
cocrystallograph
studi
provid
differ
approach
directli
manipul
broaden
specif
altern
antigendriven
passiv
select
studi
indic
vl
make
signific
intermolecular
contact
notabl
critic
contact
amino
acid
lie
within
predict
hot
spot
aid
mediat
shm
combinatori
light
chain
shuffl
report
previous
provid
divers
drift
viral
epitop
recognit
focu
singl
vl
cdr
hot
spot
alon
immun
strategi
broaden
nab
activ
report
therefor
explor
chain
shuffl
focus
mutagenesi
amino
acid
strategi
broaden
fine
specif
overcom
resist
mutat
case
small
librari
found
necessari
isol
novel
nab
desir
properti
tabl
vk
shuffl
librari
select
result
five
new
ab
three
ab
broadli
neutral
four
viral
strain
remark
sequenc
analysi
reveal
common
featur
ab
amino
acid
chang
region
posit
consensu
chang
srn
posit
potenc
broad
neutral
enhanc
posit
neutral
rrn
chang
addit
fmderiv
phage
display
librari
carri
satur
mutat
amino
acid
result
isol
five
bnab
activ
four
viral
strain
importantli
consensu
chang
found
parent
mutat
chang
maintain
thu
specif
high
affin
potent
nab
origin
target
sarscov
success
broaden
becom
activ
viral
strain
includ
escap
mutant
without
compromis
origin
potenc
studi
suggest
even
without
crystal
structur
inform
select
chain
vh
vl
shuffl
librari
escap
mutant
like
provid
import
paratop
inform
region
could
account
escap
parent
ab
likewis
shm
hotspot
target
mutagenesi
strategi
may
similar
great
valu
combin
known
structur
final
develop
singl
nab
nab
combin
suffici
breadth
protect
multipl
viral
strain
includ
escap
mutant
may
aris
futur
zoonot
transfer
great
import
one
strategi
term
converg
combin
immunotherapi
cci
focus
appli
intens
nab
immun
pressur
singl
overlap
neutral
epitop
neutral
escap
prevent
would
occur
great
cost
viral
fit
structur
data
sarscov
evolut
provid
support
concept
certain
mutat
overlap
epitop
eg
result
circa
loss
bind
affin
success
broaden
nab
specif
includ
domin
neutral
escap
pathway
first
step
test
import
hypothesi
engin
broad
nab
andor
variant
could
use
either
alon
combin
manipul
viru
evolut
compromis
fit
ab
blockad
escap
pathway
approach
like
diverg
combin
immunotherapi
dci
target
two
nonoverlap
neutral
epitop
address
work
repres
anoth
import
tactic
could
use
potent
nab
discov
similar
manner
mab
therapi
vaccin
strategi
could
design
produc
bnab
recogn
potenti
escap
variant
natur
occur
inde
inclus
vitro
deriv
escap
variant
promot
aidmedi
sequenc
diversif
germin
center
bcell
vaccin
strategi
worth
investig
also
includ
studi
six
civet
serum
sampl
collect
xinyuan
anim
market
guangzhou
prior
cull
jan
one
sampl
collect
sarslikecov
neg
civet
cat
use
control
serum
sampl
collect
china
cdc
virologist
verifi
antisarscov
ab
posit
detect
enzymelink
immunoabsorb
assay
elisa
use
commerci
avail
diagnost
kit
civet
cat
sampl
verifi
posit
sarslikecov
rtpcr
n
p
gene
sera
heatinactiv
min
prior
perform
experi
fulllength
gene
sarscov
gener
de
novo
recurs
pcr
variant
contain
mutant
gener
sitedirect
mutagenesi
use
gene
templat
plasmid
encod
fulllength
protein
wild
type
variant
sarscov
construct
make
pseudotyp
virus
sproteinpseudotyp
lentivirus
express
luciferas
report
gene
produc
describ
previous
briefli
cell
cotransfect
plasmid
encod
fulllength
protein
variant
plasmid
encod
gagpol
plasmid
phivluc
encod
firefli
luciferas
report
gene
control
long
termin
repeat
fortyeight
hour
posttransfect
viral
supernat
harvest
neutral
assay
test
antibodi
sera
differ
dilut
incub
adequ
amount
sproteinpseudotyp
virus
min
room
temperatur
rt
mixtur
ad
cell
well
plate
infect
effici
quantifi
measur
luciferas
activ
target
cell
eg
g
berthold
micropl
luminomet
lb
gener
character
neutral
escap
variant
escap
mutant
gener
incub
equal
volum
ml
wildtyp
sarscov
urbani
strain
pfuml
ugml
ab
give
inhibit
viral
infect
h
co
mixtur
ad
monolay
vero
cell
plate
incub
cell
h
co
viru
remov
cell
wash
twice
dmem
medium
final
cell
overlaid
ml
fbsdmem
cultur
medium
contain
concentr
agaros
incub
day
ml
neutral
red
ad
well
left
plate
overnight
incub
next
day
isol
escap
viru
plaqu
pick
transfer
medium
freezethaw
time
plaquepick
viru
propag
vero
cell
presenc
three
passag
cytopath
effect
cpe
evid
passag
virus
incub
plaqu
assay
confirm
resist
phenotyp
gener
plaquepurifi
subclon
mutant
virus
subclon
escap
viru
mutant
propag
aliquot
store
identifi
possibl
mutat
sarscov
spike
protein
escap
virus
viral
rna
escap
virus
wildtyp
sarscov
viru
isol
convert
cdna
standard
rtpcr
pcr
product
clone
topoclon
vector
invitrogen
clone
pcr
product
analyz
nucleotid
sequenc
sarscov
spike
plasmid
encod
rbd
residu
fuse
ctermin
tag
transfect
express
mutant
rbd
construct
sitedirect
mutagenesi
made
use
templat
ab
nation
cell
cultur
center
conjug
protein
sepharos
use
affin
purif
construct
librari
vh
variabl
region
heavi
chain
gene
clone
ncoibspei
fragment
vector
pfarbervkrep
contain
repertoir
nonimmun
vk
gene
deriv
healthi
donor
ligat
dna
transform
eclectroporationcompet
e
coli
cell
follow
manufactur
instruct
stratagen
la
jolla
ca
three
transform
perform
gener
scfv
contain
pfarber
phagemid
use
dna
templat
target
residu
mutat
amino
acid
use
degener
oligonucleotid
contain
random
nnk
codon
n
atgc
k
gt
quikchang
method
stratagen
nnk
codon
encod
amino
acid
uag
stop
codon
suppress
supe
ecoli
bacteri
strain
mutat
dna
electropor
cell
gener
phage
antibodi
librari
produc
describ
use
pan
select
select
phage
librari
screen
phage
antibodi
three
human
nonimmun
scfv
librari
use
studi
two
total
member
construct
peripher
blood
bcell
unimmun
donor
lab
mehta
iii
librari
third
one
construct
healthi
donor
fox
chase
cancer
center
librari
fmlibrari
describ
pfu
phagescfv
prepar
librari
use
select
scfv
differ
rbd
target
separ
purifi
rbd
either
coat
maxisorp
immunotub
nunc
napervil
il
conjug
magnet
bead
dynabead
epoxi
dynal
inc
follow
manufactur
instruct
immunotubebound
beadscoupl
protein
incub
phagescfv
differ
librari
nonspecif
absorb
phage
remov
intens
wash
pbst
pb
contain
tween
specif
bound
phage
elut
mm
triethylamin
neutral
tri
ph
infect
ecoli
amplifi
use
select
describ
previous
randomli
pick
singl
phagescfv
clone
screen
specif
bind
differ
rbd
target
elisa
two
round
pan
clone
bound
target
select
sequenc
analysi
vh
vl
chain
clone
sequenc
correspond
amino
acid
sequenc
align
identifi
uniqu
clone
phagescfv
individu
clone
produc
neutral
assay
use
method
make
phage
librari
phage
particl
concentr
time
use
pegnacl
precipit
whole
human
produc
describ
previous
brief
vh
vl
gene
fragment
select
scfv
separ
subclon
human
kappa
light
chain
lambda
light
chain
express
vector
human
express
cell
invitrogen
transient
transfect
purifi
protein
sepharos
affin
chromatographi
maxisorp
immunopl
coat
mg
antigen
per
well
control
protein
test
human
sera
ab
phageab
pb
contain
nonfat
milk
ad
competit
elisa
competit
sera
ab
premix
test
ab
min
rt
ad
specif
bound
ab
phageab
detect
ad
hrpconjug
antihuman
igg
hrplabel
respect
tmb
substrat
hrp
ad
reaction
stop
min
later
absorb
nm
measur
bind
mab
variou
rbd
anaylyz
biacor
biacor
antihuman
igg
fc
antibodi
biacor
coval
coat
sensor
chip
aminecoupl
use
coupl
kit
biacor
ab
captur
onto
antihuman
igg
fc
surfac
flow
rate
mlmin
hb
buffer
biacor
rbd
inject
flow
cell
flow
rate
ml
min
hb
buffer
concentr
rang
nm
interact
ab
nm
interact
ab
respect
buffer
inject
serv
neg
control
upon
complet
associ
dissoci
cycl
surfac
regener
mgcl
solut
associ
rate
ka
dissoci
rate
constant
kd
affin
constant
kd
calcul
use
biacor
evalu
softwar
good
fit
base
agreement
experiment
data
calcul
fit
chi
valu
surfac
densiti
ab
optim
minim
mass
transfer
ka
kd
kd
report
repres
mean
standard
error
least
two
experi
oneway
anova
correl
sampl
use
measur
differ
differ
type
serum
sampl
neutral
pseudo
viral
infect
unpair
student
ttest
use
statist
analysi
differ
serum
sampl
bind
competit
abil
bind
figur
biosensorgram
bind
analysi
nab
spike
rbd
found
mb
doc
